"Wall Street expects EPS of $2.01 per share with revenue consensus at $16.12 billion."
"A meaningful beat would require EPS of at least $2.10 (4.5% above consensus) paired with revenue of $16.5 billion or higher."
"Keytruda sales reached $8.14 billion, up 10% year-over-year, demonstrating continued strength in oncology despite increasing biosimilar competition concerns"
"CEO Robert Davis emphasized "delivering value through innovative portfolio" while "securing future with pipeline investments.""
Merck will report Q4 2025 earnings on Feb. 3, 2026 before market open with Wall Street expecting $2.01 in EPS and $16.12 billion in revenue, a 3.1% year-over-year increase. Analysts have reconfirmed estimates, indicating confidence in execution despite headwinds. Based on historical volatility, the stock typically moves 3%–5% on earnings surprises, and a meaningful beat is defined as EPS of at least $2.10 with revenue of $16.5 billion or more. Merck has beaten estimates three consecutive quarters with an average surprise of 5.1%, showing Keytruda strength, Gardasil weakness in China, raised full-year guidance, and ongoing Verona Pharma integration to monitor.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]